resina 2001-2014

AREVIR, Köln, 08.05.2015
RESINA 2001-2014
Dr. Björn Jensen
Klinik für Gastroenterologie, Hepatologie und Infektiologie
Universitätsklinikum Düsseldorf
The RESINA Study
(Genotypic HIV-Resistance in Treatment-Naives)
 Ongoing prospective study in Nordrhein-Westfalen
 Inclusion: Untreated HIV-infected subjects before ART initiation
 Study period: 2001-2014
 Aims of study:
– Epidemiology of primary resistance in chronically HIV-infected
patients
– Evaluation of efficacy of HAART guided by resistance testing
– Bioinformatic analysis of resistance data
– Subgroup analyses
 Classification of resistance: Shafer RW et al., Antiviral Therapy 2009
 Until end of 2014: 3811 patients (with sequence) in 36 centers
 Funding:
– Federal Ministry of Health and Social Security (BMG)
– Heinz-Ansmann-Foundation for AIDS-Research
RESINA 2001-2014
Nationality w/o SSA (n=3319)
Poland
1,1%
Brazil
0,7%
Russian Federation
1,4%
Thailand
1,7%
Turkey
2,4%
Greece Spain
0,5% 0,5%
Italy
0,9%
Portugal
France 0,4%
Netherlands
0,4%
0,3%
Ukraine
0,3%
Others (each N < 10)
5,1%
not documented
Germany
Turkey
not documented
3,5%
Thailand
Russian Federation
Poland
Italy
Brazil
Greece
Spain
France
Portugal
Netherlands
Ukraine
Others (each N < 10)
Germany
80,8%
RESINA 2001-2014
Nationality only SSA(n=372)
Cameroon
16,1%
other countries
19,1%
Sierra Leone
2,7%
Cameroon
Kenya
15,9%
Ethiopia
3,2%
Kenya
Togo
Nigeria
Cote d'Ivoire
3,8%
Ghana
Congo, Republic of (Brazzaville)
Cote d'Ivoire
Congo, Republic of
(Brazzaville)
6,7%
Ethiopia
Ghana
10,2%
Togo
11,6%
Nigeria
10,8%
Sierra Leone
other countries
RESINA 2001-2014
Subtypes (n=2797)
subtypes male patients
C
1,5%
01_AE
02_AG 3,5%
4,4%
G other
A1
4,6% 0,9% 2,1%
B
C
02_AG
01_AE
A1
G
other
B
83,1%
RESINA 2001-2014
Subtypes (n=630)
subtypes female patients
12,7%
4,9%
30,3%
B
C
02_AG
16,0%
01_AE
A1
G
9,5%
7,6%
18,9%
other
Trends of primary HIV drug resistance:
RESINA (n=3452)
16,0%
14,0%
12,0%
10,0%
any
NRTI
8,0%
NNRTI
PI
6,0%
REVERT
4,0%
2,0%
0,0%
2001-2002
2003-2004
2005-2006
2007-2008
2009-2010
2011-2012
2013-2014
Tropism:
RESINA 2001-2014 (n=325)
100,0%
90,0%
80,0%
70,0%
60,0%
X4
50,0%
X4R5
R5
40,0%
30,0%
20,0%
10,0%
0,0%
2001-2004
2005-2007
2008-2010
2011-2014
Trends of HIV drug resistance:
AREVIR (w/o RESINA, after ART)
100
90
80
70
60
% 50
40
30
20
10
0
RESINA 2001-2012
Summary
 The RESINA study provides a diverse and representative study
cohort
 TDR has to be expected in around 10% of chronically HIV-1
infected Patients
 TDR is not decreasing in this cohort despite decreasing
resistance in therapy-experienced patients;
 TDR even tends to increase overall and in the NNRTI-group
RESINA-Study Centers
Praxis Arbter, Krefeld
Praxis Mauruschat, Wuppertal
Praxis Baumann, Neuss
Praxis Mauss, Schmutz, Hegener, Düsseldorf
Praxis Becker-Boost, Duisburg
Praxis Miasnikov, Düsseldorf
Praxis Busch, Christenen, Münster
Krankenhaus der Augustinerinnen, M. Oette, Köln
Praxis Carls, Huber, Düsseldorf
Klinikum Osnabrück, A. Mutz
Praxis Dresch, Köln
Uniklinik Düsseldorf, B. Jensen, T. Feldt, D. Häussinger
Uniklinik Essen, S. Esser
Praxis Reith, Düsseldorf
Uniklinik Köln, G. Fätkenheuer
Klinik Kemperhof, A. Rieke, Koblenz
Praxis Ferdinand, Köln
Uniklinik Bonn, J. Rockstroh
Praxis Gantke, Düsseldorf
Praxis Schäfer, Bielefeld
Praxis Gippert, Hartmann, Quaing, Münster
Praxis Schoelzel, Troisdorf
Praxis Grüneberg, Münster
Praxis Scholten, Köln
Praxis Radecki, Köln
Krankenhaus Hagen, T. Scholten, Hagen
Klinikum Dortmund, M. Hower, Dortmund
Praxis Schons, Düsseldorf
Praxis Isernhagen, Römer, Qurishi, Köln
Praxis Schuster, Wuppertal
Praxis Knechten, Habets, Aachen
Praxis Stechel, Juretzko, Köln
Praxis Köthemann, Neuwirth, Köln
Praxis Strehlow, Petry, Düsseldorf
Praxis Kwirant, Duisburg
Praxis Wiesel, Theisen, Voigt, Köln
Dieter Häussinger, Mark Oette,
Stefan Reuter, Ulrike Haars, Falk Hüttig,
Abdurrahman Sagir, Carola Blondin
Department for Gastroenterology, Hepatology and Infectious Diseases
University Hospital of Düsseldorf, Germany
Rolf Kaiser, Claudia Müller, Herbert Pfister,
Eugen Schülter, Melanie Balduin, Nadine Lübke,
Finja Schweitzer, Jens Verheyen, Veronica di Cristanziano,
Elena Knops, Angelika Hergesell
Institute for Virology, University of Köln, Germany
Thomas Lengauer and team, Niko Beerenwinkel
Max Planck Institute for Bioinformatics, Saarbrücken

Download Report